Type 2 diabetes phenotype A (n = 77) | Type 2 diabetes phenotype B (n = 45) | Control group | ANOVA | |
---|---|---|---|---|
(n = 54) | p-value | |||
Age (years) | 60 ± 11 | 56 ± 11 a | 56 ± 14 a | 0.108 |
Male (%) | 65.9 | 64.6 | 57.4 a, b | <0.001 |
BMI (kg/m2) | 29.6 ± 6.2 | 31.1 ± 4 a | 25.9 ± 3.6 a, b | <0.001 |
Waist (cm) | 104 ± 15 | 108 ± 13 a | 92 ± 11 a, b | <0.001 |
Diabetes duration (years) | 12 ± 11 | 9 ± 8 a | - | |
Insulin use (%) | 58 | 52 a | - | |
Lipid lowering drugs (%) | 30 | 28 | - | |
HbA1c (%) | 9.1 ± 2.1 | 9.6 ± 2.3 a | 5.3 ± 0.6 a, b | <0.001 |
Hypertension (%) 1 | 69.4 | 68.2 | - | |
Retinopathy (%) | 29.6 | 29.5 | - | |
Albuminuria (%) | 24 | 29.6 a | - | |
Coronary heart disease (%) 2 | 5.6 | 15.9 a | - | |
Total cholesterol (mmol/L) | 4.78 ± 1.09 | 5.64 ± 1.53 a | 5.00 ± 0.79 b | 0.004 |
Triglycerides (mmol/L) | 1.46 ± 0.79 | 3.89 ± 3.30 a | 0.87 ± 0.37 a,b | <0.001 |
VLDLc (mmol/L) | 0.65 ± 0.30 | 1.43 ± 1.12 a | 0.40 ± 0.17 a,b | <0.001 |
LDLc (mmol/L) | 2.86 ± 0.95 | 3.10 ± 0.96 a | 2.94 ± 0.66 b | 0.281 |
HDLc (mmol/L) | 1.28 ± 0.33 | 1.02 ± 0.27 a | 1.64 ± 0.37 a,b | <0.001 |
NEFA (mmol/L) | 0.64 ± 0.29 | 0.90 ± 0.48 | 0.41 ± 0.19 a,b | <0.001 |
apoB (g/L) | 0.93 ± 0.32 | 1.09 ± 0.28 a | 0.80 ± 0.19 a,b | <0.001 |
apoA-I (g/L) | 1.46 ± 0.24 | 1.37 ± 0.25 a | 1.57 ± 0.31 a,b | 0.001 |
apoA-II (g/L) | 0.33 ± 0.07 | 0.34 ± 0.06 | 0.35 ± 0.05 | 0.081 |
LDL size (nm) | 26.0 ± 0.4 | 25.0 ± 0.4 a | 26.3 ± 0.1 b | <0.001 |